A new therapeutic antibody masks ErbB2 to its partners

被引：68

作者：

Badache, A ^{[1
]}

Hynes, NE ^{[1
]}

机构：

[1] Novartis Res Fdn, Friedrich Miescher Inst, CH-4002 Basel, Switzerland

来源：

CANCER CELL | 2004年 / 5卷 / 04期

关键词：

D O I：

10.1016/S1535-6108(04)00088-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In cancer cells, the ErbB2 receptor tyrosine kinase can be activated in two ways: by overexpression or by ligand-mediated stimulation of another ErbB receptor. The ErbB2-targeting antibody trastuzumab (Herceptin) is used for treatment of metastatic breast cancer patients whose tumors overexpress ErbB2. A new structural study in this issue of Cancer Cell reveals how targeting ErbB2 with another antibody, pertuzumab (Omnitarg), prevents ligand-induced dimerization of ErbB2 with the other ErbB receptors. Pertuzumab's novel mode of action might offer additional therapeutic opportunities for treatment of tumors expressing ligand-activated ErbB2.

引用

页码：299 / 301

页数：3

共 9 条

[1] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, DB
Akita, RW
Fox, WD
Lewis, GD
Higgins, B
Pisacane, PI
Lofgren, JA
Tindell, C
Evans, DP
Maiese, K
Scher, HI
Sliwkowski, MX
[J]. CANCER CELL, 2002, 2 (02) : 127 - 137
[2] An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors
Burgess, AW
Cho, HS
Eigenbrot, C
Ferguson, KM
Garrett, TPJ
Leahy, DJ
Lemmon, MA
Sliwkowski, MX
Ward, CW
Yokoyama, S
[J]. MOLECULAR CELL, 2003, 12 (03) : 541 - 552
[3] Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, HS
Mason, K
Ramyar, KX
Stanley, AM
Gabelli, SB
Denney, DW
Leahy, DJ
[J]. NATURE, 2003, 421 (6924) : 756 - 760
[4] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, RA
Towers, TL
Presta, LG
Ravetch, JV
[J]. NATURE MEDICINE, 2000, 6 (04) : 443 - 446
[5] The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors
Garrett, TPJ
McKern, NM
Lou, MZ
Elleman, TC
Adams, TE
Lovrecz, GO
Kofler, M
Jorissen, RN
Nice, EC
Burgess, AW
Ward, CW
[J]. MOLECULAR CELL, 2003, 11 (02) : 495 - 505
[6] ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
GrausPorta, D
Beerli, RR
Daly, JM
Hynes, NE
[J]. EMBO JOURNAL, 1997, 16 (07) : 1647 - 1655
[7] The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
Holbro, T
Beerli, RR
Maurer, F
Koziczak, M
Barbas, CF
Hynes, NE
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (15) : 8933 - 8938
[8] Molina MA, 2001, CANCER RES, V61, P4744
[9] Untangling the ErbB signalling network
Yarden, Y
Sliwkowski, MX
[J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (02) : 127 - 137

← 1 →